Estados Unidos · Plataformas y datos · Stocktwits

Compass Pathways To Complete COMP360 FDA Filing Within Two Weeks — CEO Nath Eyes Launch In First Half Of 2027

Publicado por Stocktwits · Estados Unidos hace 9 h

The drugmaker reported a diluted net loss of $0.31 per share in Q3, beating analysts’ expectations of a $0.41 per share loss, according to Fiscal.ai. Compass ended September with…

Leer el artículo completo en Stocktwits Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (stocktwits.com)

Compass Pathways To Complete COMP360 FDA Filing Within Two Weeks — CEO Nath Eyes Launch In First Half Of 2027

También te puede interesar

SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?

Tech borrowers are picking up the tab: debt premium hits a 23-year high

Texas governor race tightens in prediction markets, but Abbott remains favored

‘It’s good to be old’: I’ve been invited to a dozen free meals that turn into annuity sales pitches. Should I stop going?

ICF vs. HAUZ: ICF Beats on Returns, but HAUZ Dominates on Fees and Yield

Treasury yields edge up as Election Day meets JOLTS, refunding

Compass Pathways To Complete COMP360 FDA Filing Within Two Weeks — CEO Nath Eyes Launch In First Half Of 2027

Compartir

También te puede interesar

SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?

Tech borrowers are picking up the tab: debt premium hits a 23-year high

Texas governor race tightens in prediction markets, but Abbott remains favored

‘It’s good to be old’: I’ve been invited to a dozen free meals that turn into annuity sales pitches. Should I stop going?

ICF vs. HAUZ: ICF Beats on Returns, but HAUZ Dominates on Fees and Yield

Treasury yields edge up as Election Day meets JOLTS, refunding